• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Director Bailey Gregory bought $17,745 worth of shares (3,866 units at $4.59), increasing direct ownership by 6% to 67,243 units (SEC Form 4)

    12/19/24 4:05:12 PM ET
    $SER
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SER alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Bailey Gregory

    (Last) (First) (Middle)
    601 GENOME WAY,
    SUITE 2001

    (Street)
    HUNTSVILLE AL 35806

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Serina Therapeutics, Inc. [ SER ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    12/17/2024
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 12/17/2024 P 3,866 A $4.5899(1) 67,243 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. The price reflects the weighted average purchase price of multiple transactions ranging from a low of $4.54 per share to a high of $4.74 per share. Upon the written request of the SEC, the issuer or a security holder of the issuer, the reporting person agrees to provide the number of shares sold at each sale price.
    /s/ Gregory Bailey 12/17/2024
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $SER alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SER

    DatePrice TargetRatingAnalyst
    7/14/2025$15.00Buy
    H.C. Wainwright
    More analyst ratings

    $SER
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Bailey Gregory bought $17,745 worth of shares (3,866 units at $4.59), increasing direct ownership by 6% to 67,243 units (SEC Form 4)

    4 - Serina Therapeutics, Inc. (0001708599) (Issuer)

    12/19/24 4:05:12 PM ET
    $SER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Bailey Gregory bought $6,851 worth of shares (1,137 units at $6.03), increasing direct ownership by 2% to 63,377 units (SEC Form 4)

    4 - Serina Therapeutics, Inc. (0001708599) (Issuer)

    9/24/24 4:30:06 PM ET
    $SER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Bailey Gregory bought $88,257 worth of shares (14,388 units at $6.13), increasing direct ownership by 30% to 62,240 units (SEC Form 4)

    4 - Serina Therapeutics, Inc. (0001708599) (Issuer)

    9/20/24 6:59:29 PM ET
    $SER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SER
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Scientific Officer Moreadith Randall exercised 47,674 shares at a strike of $0.06 and sold $331,418 worth of shares (47,674 units at $6.95) (SEC Form 4)

    4 - Serina Therapeutics, Inc. (0001708599) (Issuer)

    8/27/25 5:16:39 PM ET
    $SER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Scientific Officer Moreadith Randall exercised 4,304 shares at a strike of $0.06 and sold $22,284 worth of shares (4,304 units at $5.18) (SEC Form 4)

    4 - Serina Therapeutics, Inc. (0001708599) (Issuer)

    8/20/25 5:13:25 PM ET
    $SER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Scientific Officer Moreadith Randall exercised 5,500 shares at a strike of $0.06 and sold $28,875 worth of shares (5,500 units at $5.25) (SEC Form 4)

    4 - Serina Therapeutics, Inc. (0001708599) (Issuer)

    8/14/25 4:27:41 PM ET
    $SER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SER
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright initiated coverage on Serina Therapeutics with a new price target

    H.C. Wainwright initiated coverage of Serina Therapeutics with a rating of Buy and set a new price target of $15.00

    7/14/25 8:54:25 AM ET
    $SER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SER
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Serina Therapeutics Secures Up to $20 Million to Advance Registrational Trial of SER-252 in Parkinson's Disease

    Transaction structured to provide flexible funding to support Phase 1b registrational clinical study program in advanced Parkinson's under the 505(b)(2) NDA pathwayEvaluating complementary funding including strategic equity and non-dilutive alternatives HUNTSVILLE, AL, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. ("Serina") (NYSE:SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, today announced that it has entered into an agreement to access up to $20 million in financing led by Serina Board Director Greg Bailey, MD. The financing also includes the issuance of warrants which, if fully issued and exercised,

    9/9/25 3:20:56 PM ET
    $SER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Serina Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

    HUNTSVILLE, AL, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. ("Serina") (NYSE:SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, announced that Steve Ledger, Chief Executive Officer, will present at the H.C. Wainwright 27th Annual Global Investment Conference in New York, NY on September 8, 2025, at 9:30 a.m. ET. A live webcast of the presentation will be accessible to registered attendees at this link. An archived replay will be available on-demand for 90 days following the event. About Serina Therapeutics Serina is a clinical-stage biotechnology company developing a pipeline of wholly owned drug product c

    9/8/25 6:00:00 AM ET
    $SER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Serina Therapeutics Announces FDA Feedback Supports Registrational Trial Design of SER-252 in Advanced Parkinson's Disease under 505(b)(2) NDA Pathway

    - U.S. IND filing planned for Q4 2025 with U.S. enrollment expected to start in Q1 2026 - Patient dosing expected to begin in Australia in Q4 2025 HUNTSVILLE, AL, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. ("Serina") (NYSE:SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, today announced that following a recent Type B meeting with the U.S. Food and Drug Administration (FDA), the FDA's written feedback supports advancing SER-252 (POZ-apomorphine) in a registrational clinical study program in advanced Parkinson's under the 505(b)(2) NDA pathway. "People living with advanced Parkinson's need more consisten

    8/25/25 4:15:00 PM ET
    $SER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SER
    SEC Filings

    View All

    SEC Form PRE 14A filed by Serina Therapeutics Inc.

    PRE 14A - Serina Therapeutics, Inc. (0001708599) (Filer)

    9/15/25 5:06:05 PM ET
    $SER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Serina Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

    8-K - Serina Therapeutics, Inc. (0001708599) (Filer)

    9/15/25 4:01:24 PM ET
    $SER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Serina Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Serina Therapeutics, Inc. (0001708599) (Filer)

    9/9/25 3:23:30 PM ET
    $SER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SER
    Leadership Updates

    Live Leadership Updates

    View All

    Serina Therapeutics Appoints Stephen Brannan, M.D. to Board of Directors

    - Renowned neuroscience drug developer joins to support strategic development of long-acting CNS therapeutics – HUNTSVILLE, AL, May 22, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. ("Serina") (NYSE:SER), a clinical-stage biotechnology company developing a pipeline of product candidates leveraging its proprietary POZ Platform™ drug optimization technology, today announced the appointment of Stephen (Steve) Brannan, M.D., to its Board of Directors. Dr. Brannan brings more than three decades of experience in neuroscience and neuropsychiatry drug development, with a proven track record of leading clinical programs from early development through regulatory approval and commercialization

    5/22/25 4:50:00 PM ET
    $SER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Serina Therapeutics Appoints Dr. Jay Venkatesan to its Board of Directors

    HUNTSVILLE, AL, Feb. 12, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. ("Serina") (NYSE:SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, today announced the appointment of Jay Venkatesan, MD, MBA, to its Board of Directors. Dr. Venkatesan brings deep expertise in biotechnology investment, company building, and strategic growth, having successfully led and advised multiple biopharma companies through pivotal stages of development, including high-profile mergers and acquisitions. Dr. Venkatesan most recently served as Chairman, President, and CEO of Angion Biomedica until its merger with Elicio Therapeutics in 2023. He

    2/12/25 4:15:00 PM ET
    $SER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Serina Therapeutics Welcomes Karen J. Wilson to its Board of Directors

    HUNTSVILLE, AL, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. ("Serina") (NYSE:SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug delivery technology, today announced the appointment of Karen J. Wilson to the Board of Directors. "We are excited to welcome Karen to the Board of Directors. Karen's financial expertise and deep understanding of the biotech landscape will play a crucial role in guiding our strategic initiatives and delivering transformative therapies to patients," said Steve Ledger, Serina's Chief Executive Officer. Ms. Wilson brings over three decades of leadership experiences in the life sciences sector. She currently se

    1/14/25 5:25:00 PM ET
    $SER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SER
    Financials

    Live finance-specific insights

    View All

    Serina Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Highlights

    HUNTSVILLE, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. ("Serina") (NYSE:SER), a clinical-stage biotechnology company advancing its lead IND candidate, SER-252, for advanced Parkinson's disease, enabled by its proprietary POZ Platform™ drug optimization technology, today announced its financial results for the second quarter ended June 30, 2025, along with key recent updates. "We're proud of the momentum we've built across our development programs. With SER-252 on track to enter the clinic later this year and the recent advancement of SER-270 for tardive dyskinesia, we are demonstrating how the POZ Platform can enable differentiated, long-acting therapies across neurologic

    8/11/25 4:30:00 PM ET
    $SER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Serina Therapeutics Announces Date for 2025 Annual Stockholders Meeting

    HUNTSVILLE, July 01, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. ("Serina") (NYSE:SER), a clinical-stage biotechnology company, today announced that its Board of Directors has established November 7, 2025, as the date of its 2025 annual meeting of stockholders (the "Annual Meeting"). The time and location of the Annual Meeting will be set forth in the Serina's definitive proxy statement for the Annual Meeting to be filed with the Securities and Exchange Commission (the "SEC"). Because the date of the Annual Meeting represents a change of more than 30 days from the anniversary of Serina's 2024 annual meeting of stockholders, the deadline for stockholder proposals to be submitted pur

    7/1/25 4:15:00 PM ET
    $SER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Serina Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights

    On track for first patient dosing of SER-252 in Phase 1b clinical trial in advanced Parkinson's disease in Q4 2025Strengthened balance sheet with recent financingAdvancing innovative POZ Platform across multiple therapeutic modalitiesTwo new seasoned biotech leaders added to the Board of Directors HUNTSVILLE, May 08, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. ("Serina") (NYSE:SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, today reported its financial results for the first quarter ended March 31, 2025, along with recent business highlights. "We are energized by the substantial progress and strengthened foundation

    5/8/25 4:23:00 PM ET
    $SER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SER
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Serina Therapeutics Inc.

    SC 13D/A - Serina Therapeutics, Inc. (0001708599) (Subject)

    12/9/24 4:45:59 PM ET
    $SER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Serina Therapeutics Inc.

    SC 13G/A - Serina Therapeutics, Inc. (0001708599) (Subject)

    11/14/24 5:09:38 PM ET
    $SER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Serina Therapeutics Inc.

    SC 13D/A - Serina Therapeutics, Inc. (0001708599) (Subject)

    7/5/24 4:01:13 PM ET
    $SER
    Biotechnology: Pharmaceutical Preparations
    Health Care